Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $23.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors surrounding EyePoint Pharmaceuticals’ promising developments and strategic advancements. The company has recently completed enrollment for its Phase 3 trials, LUGANO and LUCIA, which focus on the DURAVYU treatment for wet AMD. These trials are significant as they could position DURAVYU as the first long-acting TKI for wet AMD to potentially file for an NDA and enter the market.
Additionally, EyePoint is advancing DURAVYU into a Phase 3 program for diabetic macular edema (DME), with patient dosing expected to start in the first quarter of 2026. The drug’s potential to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME adds to its appeal. These strategic moves, along with management’s expectations for a timely U.S. launch if approved, underpin the Buy rating and the $23 price target set by Yi Chen.
According to TipRanks, Chen is an analyst with an average return of -4.3% and a 41.32% success rate. Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, VolitionRX, and Alpha Tau Medical Ltd.
In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.